WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414600
Description: Orazipone inhibits cytokine production and histamine release; an NSAID.
MedKoo Cat#: 414600
Chemical Formula: C13H14O4S
Exact Mass: 266.0613
Molecular Weight: 266.31
Elemental Analysis: C, 58.63; H, 5.30; O, 24.03; S, 12.04
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Orazipone; OR-1384; OR1384; OR 1384
IUPAC/Chemical Name: 3-(p-(Methylsulfonyl)benzylidene)-2,4-pentanedione
InChi Key: CAWYWWPWSAMGBV-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H14O4S/c1-9(14)13(10(2)15)8-11-4-6-12(7-5-11)18(3,16)17/h4-8H,1-3H3
SMILES Code: CC(/C(C(C)=O)=C/C1=CC=C(S(=O)(C)=O)C=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 266.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Sareila O, Hämäläinen M, Nissinen E, Kankaanranta H, Moilanen E. Orazipone inhibits activation of inflammatory transcription factors nuclear factor-kappa B and signal transducer and activator of transcription 1 and decreases inducible nitric-oxide synthase expression and nitric oxide production in response to inflammatory stimuli. J Pharmacol Exp Ther. 2008 Feb;324(2):858-66. doi: 10.1124/jpet.107.129114. Epub 2007 Nov 26. PMID: 18039960.
2: Boerma M, Wang J, Richter KK, Hauer-Jensen M. Orazipone, a locally acting immunomodulator, ameliorates intestinal radiation injury: a preclinical study in a novel rat model. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):552-9. doi: 10.1016/j.ijrobp.2006.05.067. PMID: 16965997.
3: Kankaanranta H, Ilmarinen P, Zhang X, Nissinen E, Moilanen E. Antieosinophilic activity of orazipone. Mol Pharmacol. 2006 Jun;69(6):1861-70. doi: 10.1124/mol.105.021170. Epub 2006 Mar 15. PMID: 16540599.
4: Vendelin J, Laitinen C, Vainio PJ, Nissinen E, Mäki T, Eklund KK. Novel sulfhydryl-reactive compounds orazipone and OR-1958 inhibit cytokine production and histamine release in rat and human mast cells. Int Immunopharmacol. 2005 Jan;5(1):177-84. doi: 10.1016/j.intimp.2004.07.020. PMID: 15589479.